[
    [
        {
            "time": "",
            "original_text": "年初“押错题”现迎加强版 国内四价流感疫苗生产首获批",
            "features": {
                "keywords": [
                    "四价流感疫苗",
                    "生产获批",
                    "加强版"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "年初“押错题”现迎加强版 国内四价流感疫苗生产首获批",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "CFDA 动真格了！大批中药注射剂说明书要改",
            "features": {
                "keywords": [
                    "CFDA",
                    "中药注射剂",
                    "说明书修改"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "CFDA 动真格了！大批中药注射剂说明书要改",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "[推荐评级] 医药行业周报：谈龙头的持续上涨与二线品种的机会",
            "features": {
                "keywords": [
                    "医药行业",
                    "龙头上涨",
                    "二线品种机会"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[推荐评级] 医药行业周报：谈龙头的持续上涨与二线品种的机会",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "研发一年豪掷近50亿 国内药企三巨头产品究竟有多牛？",
            "features": {
                "keywords": [
                    "研发",
                    "药企三巨头",
                    "投入50亿"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "研发一年豪掷近50亿 国内药企三巨头产品究竟有多牛？",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-06-11",
            "original_text": "【医药-复星医药(600196)】江琦、张天翼：阿法骨化醇通过一致性评价，利妥昔单抗新适应症启动III期临床",
            "features": {
                "keywords": [
                    "复星医药",
                    "阿法骨化醇",
                    "一致性评价",
                    "利妥昔单抗",
                    "III期临床"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【医药-复星医药(600196)】江琦、张天翼：阿法骨化醇通过一致性评价，利妥昔单抗新适应症启动III期临床",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "重庆药友制药阿法骨化醇片通过一致性评价",
            "features": {
                "keywords": [
                    "重庆药友制药",
                    "阿法骨化醇片",
                    "一致性评价"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "重庆药友制药阿法骨化醇片通过一致性评价",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "四部门组织建设专项 支持创新药研发和产业化(受益股)",
            "features": {
                "keywords": [
                    "四部门",
                    "创新药",
                    "研发产业化",
                    "支持政策"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "四部门组织建设专项 支持创新药研发和产业化(受益股)",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 5,
                "Market_Scope": 10,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]